

IDS 10/06/2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Not for submission under 37 CFR 1.99)</small>	Application Number		10848827	
	Filing Date		2004-05-19	
	First Named Inventor		Phillip A. Patten	
	Art Unit		1647	
	Examiner Name		Seharaseyon, J.	
	Attorney Docket Number		0269us410	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
JS	1	20040030101	A1	2004-02-12	Bailon, et al.	
JS	2	20040223950	A1	2004-11-11	Brugger, et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
JS	1	0052153	WO	A2	2000-09-08	Maxygen, Inc.		<input type="checkbox"/>
JS	2	2004045648	WO	A1	2004-06-03	F. Hoffmann-La Roche AG		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10848827
Filing Date	2004-05-19
First Named Inventor	Phillip A. Patten
Art Unit	1647
Examiner Name	Seharaseyon, J.
Attorney Docket Number	0269us410

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
JS	1	GOEDDEL D.V., et al. The structure of eight distinct cloned human leukocyte interferon cDNAs. Nature, 1981 Mar 5; vol. 290(5801):20-26.	<input type="checkbox"/>
JS	2	BAILON P., et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjugate Chemistry, 2001 Mar-Apr; vol. 12(2):195-202.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	12/05/2006
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

IDS 10/27/2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Not for submission under 37 CFR 1.99)</small>	Application Number	10848827
	Filing Date	2004-05-19
	First Named Inventor	Phillip A. Patten
	Art Unit	1647
	Examiner Name	Seharaseyon, J.
	Attorney Docket Number	0269us410

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
JS	1	4414150		1983-11-08	Goeddel, D.	
	2	4885166		1989-12-05	Meyer, F. et al.	
	3	4695623		1987-09-22	Stabinsky, Y.	
	4	4885166		1989-12-05	Meyer, F. et al.	
	5	5985262		1999-11-16	Kinstler, O. et al.	
↓	6	6610830	B1	2003-08-26	Goeddel D. et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number	10848827
		Filing Date	2004-05-19
		First Named Inventor	Phillip A. Patten
		Art Unit	1647
		Examiner Name	Seharaseyon, J.
		Attorney Docket Number	0269us410

JS	1	20040002474	A1	2004-01-01	Heinrichs, V. et al.	
----	---	-------------	----	------------	----------------------	--

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T5
JS	1	0051873	EP	A2	1982-05-19	Genentech, Inc.		<input type="checkbox"/>
	2	0205404	EP	A2	1986-12-17	Ciba-Geigy AG		<input type="checkbox"/>
	3	0422697	EP	A1	1991-04-17	Amgen, Inc.		<input type="checkbox"/>
	4	0809996	EP	A2	1997-12-03	F. Hoffmann-La Roche AG		<input type="checkbox"/>
	5	0911033	EP	A2	1999-04-28	Amgen, Inc.		<input type="checkbox"/>
	6	20020067105	KR		2002-08-22	SunBio, Inc.		<input checked="" type="checkbox"/>
▼	7	8302461	WO	A1	1983-07-21	Cetus Corp.		<input type="checkbox"/>
	8	9206707	WO	A1	1992-04-30	Amgen, Inc.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10848827	
Filing Date	2004-05-19	
First Named Inventor	Phillip A. Patten	
Art Unit	1647	
Examiner Name	Seharaseyon, J.	
Attorney Docket Number	0269us410	

JS	9	9524212	WO	A1	1995-09-14	Imperial College	<input type="checkbox"/>
	10	9903887	WO	A1	1999-01-28	Bolder Biotechnology, Inc	<input type="checkbox"/>
	11	0042175	WO	A1	2000-07-20	Bolder Biotechnology, Inc	<input type="checkbox"/>
	12	0125438	WO	A2	2001-04-12	Maxygen, Inc.	<input type="checkbox"/>
↓	13	0187925	WO	A2	2001-11-22	Bolder Biotechnology, Inc	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
JS	1	ALLEN G., DIAZ M.O. (1996) Nomenclature of the human interferon proteins. J. Interferon Cytokine Res. 1996 Feb; 16(2):181-184.	<input type="checkbox"/>
JS	2	ALTON, K. et al. (1983) Production, characterization and biological effects of recombinant DNA derived IFN-alpha and IFN-gamma analogs. in The Biology of the Interferon System, 1983, eds. E. DeMaeyer and H. Schellekens, Elsevier Science Publications pp. 119-128.	<input type="checkbox"/>
JS	3	ALTROCK B.W., et al. (1986) Antiviral and antitumor effects of a human interferon analog, IFN-alpha Con1, assessed in hamsters. J Interferon Res. 1986 Aug; 6(4):405-415.	<input type="checkbox"/>
JS	4	BLATT L.M., et al. (1996) The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res. 1996 Jul; 16(7):489-499.	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>		Application Number	10848827
		Filing Date	2004-05-19
		First Named Inventor	Phillip A. Patten
		Art Unit	1647
		Examiner Name	Seharaseyon, J.
Attorney Docket Number		0269us410	

JS	5	CHANG C.C., et al. (1999) Evolution of a cytokine using DNA family shuffling. Nat Biotechnol. 1999 Aug;17 (8):793-797.	<input type="checkbox"/>
	6	CHEETHAM B.F., et al. (1991) Structure-function studies of human interferons-alpha: enhanced activity on human and murine cells. Antiviral Res. 1991 Jan;15(1):27-39.	<input type="checkbox"/>
	7	DIAZ M.O., et al. (1996) Nomenclature of the human interferon genes. J Interferon Cytokine Res. 1996 Feb;16 (2):179-180.	<input type="checkbox"/>
	8	FISH E.N., et al. (1989) The role of three domains in the biological activity of human interferon-alpha. J Interferon Res. 1989 Feb;9(1):97-114.	<input type="checkbox"/>
	9	FOSER S, et al. (2003) Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). Protein Expr Purif. 2003 Jul;30(1):78-87.	<input type="checkbox"/>
	10	GANGEMI J.D., et al. (1989) Significant differences in therapeutic responses to a human interferon-alpha B/D hybrid in Rauscher or Friend murine leukemia virus infections. J Interferon Res. 1989 Jun;9(3):275-283.	<input type="checkbox"/>
	11	HENCO K., et al. (1985) Structural relationship of human interferon alpha genes and pseudogenes. J Mol Biol. 1985 Sep 20;185(2):227-260.	<input type="checkbox"/>
	12	MEISTER A., et al. (1986) Biological activities and receptor binding of two human recombinant interferons and their hybrids. J Gen Virol. 1986 Aug; 67 (Pt 8):1633-1643.	<input type="checkbox"/>
	13	OZES O.N., et al. (1992) A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res. 1992 Feb;12(1):55-59.	<input type="checkbox"/>
↓	14	WECK P.K., et al. (1981) Antiviral activities of hybrids of two major human leukocyte interferons. Nucleic Acids Res. 1981 Nov 25; 9(22):6153-6166.	<input type="checkbox"/>
	15	<u>International Search Report dated July 2, 2004 for related PCT application PCT/US03/36682 filed Nov. 17, 2003</u>	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10848827
	Filing Date	2004-05-19
	First Named Inventor	Phillip A. Patten
	Art Unit	1647
	Examiner Name	Seharaseyon, J.
	Attorney Docket Number	0269us410

16	Written Opinion dated Sept. 15, 2004 for related PCT application PCT/US03/36602 filed Nov. 17, 2003	<input type="checkbox"/>
----	--	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	12/05/2006
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

IDS 11/08/2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Not for submission under 37 CFR 1.99)</small>	Application Number		10848827	
	Filing Date		2004-05-19	
	First Named Inventor		Phillip A. Patten	
	Art Unit		1647	
	Examiner Name		Seharaseyon, J.	
	Attorney Docket Number		0269us410	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
JS	1	6303344		2001-10-16	Patten, Phillip A.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
JS	1	0069913	WO	A1	2000-11-23	Lexigen Pharmaceuticals		<input type="checkbox"/>
JS	2	0244197	WO	A2	2002-06-06	Fish, Eleanor N.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10848827
Filing Date	2004-05-19
First Named Inventor	Phillip A. Patten
Art Unit	1647
Examiner Name	Seharaseyon, J.
Attorney Docket Number	0269us410

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Supplementary Partial European Search Report for related application EP 03011602, dated March 9, 2000	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	12/05/2006
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

IDS 11/14/2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Not for submission under 37 CFR 1.99)</small>	Application Number	10848827
	Filing Date	2004-05-19
	First Named Inventor	Phillip A. Patten
	Art Unit	1647
	Examiner Name	Seharaseyon, J.
	Attorney Docket Number	0269us410

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
JS	1	5382657		1995-01-17	Karasiewicz, et al.	
	2	5539063		1996-07-23	Hakimi, et al.	
	3	5559213		1996-09-24	Hakimi, et al.	
	4	5747646		1998-05-05	Hakimi, et al.	
	5	5792834		1998-08-11	Hakimi, et al.	
	6	5834594		1998-11-10	Hakimi, et al.	
↓	7	5849860		1998-12-15	Hakimi, et al.	
If you wish to add additional U.S. Patent citation information please click the Add button. Add						
U.S.PATENT APPLICATION PUBLICATIONS						Remove

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Not for submission under 37 CFR 1.99)</small>	Application Number		10848827	
	Filing Date		2004-05-19	
	First Named Inventor		Phillip A. Patten	
	Art Unit		1647	
	Examiner Name		Seharaseyon, J.	
	Attorney Docket Number		0269us410	

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T5
JS	1	0 510 356	EP	B1	1992-10-28	F. Hoffmann-La Roche AG		<input type="checkbox"/>
JS	2	0 593 868	EP	B1	1994-04-27	F. Hoffmann-La Roche AG		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T5
	1						<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	12/05/2006
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.